Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA(1c), Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy

OBJECTIVE: To examine the safety and efficacy of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, added on to pioglitazone in type 2 diabetes inadequately controlled on pioglitazone. RESEARCH DESIGN AND METHODS: Treatment-naive patients or those receiving metformin, sulfonylurea, or thiazo...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenstock, Julio, Vico, Marisa, Wei, Li, Salsali, Afshin, List, James F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3379599/
https://www.ncbi.nlm.nih.gov/pubmed/22446170
http://dx.doi.org/10.2337/dc11-1693

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3379599/
https://www.ncbi.nlm.nih.gov/pubmed/22446170
http://dx.doi.org/10.2337/dc11-1693

Ejemplares similares